Low cost 2.0 diagnostics

For more than a decade labs-on-a-chip are described as ultimate tools for personalized healthcare and point-of-care diagnostics. Biosoft scientists agree with this affirmation and work on such a motivating topic. However it is clear that there is no such technology wide sprayed today due to technical and regulatory difficulties. Lab-on-a-chip will certainly be a reality tomorrow but today medical laboratories still use 1.0 methods or expensive 2.0 protocols.

While working on long-terms innovative diagnostics tools, Biosoft also develops a full chain of technological tools to manufacture a new generation of biochips, to manage a reliable interaction with serums and to analyze with simple instrumentation and efficient software solutions the biological response of the biochip.

Our aim is to adapt our available technologies to bring in no-time to the market a low-cost platform compliant with CE-IVD standard and targeting high potential applications for medical challenges. One of the best example is certainly the allergy detection . Prick tests are still widely used (clearly 1.0 methods) with the acknowledged risk of anaphylactic shock and the wide interdiction for food-allergic patients to eat a global family of aliments. More accurate tests are available but they are expensive and non-reimbursed by health systems. Low density biochips manufactured with our novel low-cost methods on a very small surface associated with a reliable management of simple fluidic systems and instrumentation based on conventional low-cost components is able to change habits in allergy detection. Such a low-cost biochip will bring personalize medicine to the allergy specialist and will deal with Prick tests, increasing security and accuracy.

Then low-cost 2.0 diagnostics are seen by Biosoft scientists as a bridge between conventional medicine and future wide-sprayed point-of-care tools. It should address the challenges of cost competitiveness with standard methods, enhancing reliability and accuracy, a fast transfer to the market, a regulatory compliance and an understanding of the needs of the medical staffs.